Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
4.560
-0.020 (-0.44%)
Mar 20, 2026, 10:12 AM EDT - Market open

Opus Genetics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
14.210.9919.0539.850.59
Revenue Growth (YoY)
29.15%-42.30%-52.20%6665.70%-
Gross Profit
14.210.9919.0539.850.59
Selling, General & Admin
21.9818.2211.967.278.12
Research & Development
30.8154.8517.6514.3615.17
Total Operating Expenses
52.873.0729.6121.6223.29
Operating Income
-38.6-62.07-10.5618.23-22.71
Interest Expense
-1.47--1.33-0.01-0
Other Non-Operating Income (Expense)
-9.534.541.92-0.01-33.99
Total Non-Operating Income (Expense)
-10.994.540.59-0.02-33.99
Pretax Income
-49.59-57.53-9.9718.2-56.69
Provision for Income Taxes
--0.010.32-
Net Income
-49.59-57.53-9.9917.89-56.69
Net Income to Common
-49.59-57.53-9.9917.89-56.69
Shares Outstanding (Basic)
6227222015
Shares Outstanding (Diluted)
6227222115
Shares Change (YoY)
132.91%23.74%4.82%38.68%218.65%
EPS (Basic)
-0.80-2.15-0.460.90-3.82
EPS (Diluted)
-0.80-2.15-0.460.87-3.82
Free Cash Flow
-35.25-25.58-1.1114.31-19.37
Free Cash Flow Per Share
-0.57-0.96-0.050.69-1.30
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-271.90%-564.72%-55.45%45.74%-3854.84%
Profit Margin
-349.33%-523.40%-52.42%44.89%-9625.30%
FCF Margin
-248.33%-232.68%-5.84%35.92%-3288.62%
EBITDA
-38.55-62.06-10.5618.23-22.7
EBITDA Margin
-271.53%-564.63%-55.42%45.75%-3854.16%
EBIT
-38.6-62.07-10.5618.23-22.71
EBIT Margin
-271.90%-564.72%-55.45%45.74%-3854.84%
Effective Tax Rate
0.00%0.00%-0.12%1.73%0.00%
Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q